Grifols, S.A.

    Jurisdiction
    Spain
    LEI
    959800HSSNXWRKBK4N60
    ISIN
    US3984384087 (GRFS)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - General

    Scores

    InsiderPie Expert Score
    trending_flat 53 / 100
    Worse than peer group:
    55 / 100
    Fair value (Benjamin Graham formula)
    €4.81 62.2% overvalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €7.09B
    Gross margin
    38.2%
    EBIT
    €1.16B
    EBIT margin
    16.3%
    Net income
    €185.43M
    Net margin
    2.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €7.97B +12.3% €569.70M +207.2%
    €8.53B +7.0% €755.42M +32.6%
    €9.05B +6.2% €884.02M +17.0%

    Dividends

    Last dividend amount
    $0.18
    Ex date
    Payment date

    Earnings Calls

    Latest earnings call: May 12, 2025

    Add to watchlist

    Notifications